Literature DB >> 6735611

Immunoassay of ergotamine and dihydroergotamine using a common 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls.

J Rosenthaler, H Munzer, R Voges, H Andres, P Gull, G Bolliger.   

Abstract

A highly sensitive radioimmunoassay for the determination of ergotamine and dihydroergotamine is described. The limit of detection is about 9 pg/mL blood plasma for both compounds. The specificity of the gamma-globulin, which was prepared from rabbit antiserum, was investigated in the presence of compounds synthesized as possible metabolites. It was found that the tricyclic peptide moiety common to both molecules is an essential structural feature for binding to the gamma-globulin. From dilution experiments with the radioactively labelled compound it followed that ergotamine and to a lesser extent also its dihydro derivative are adsorbed on various tube wall materials using known buffer solutions. A practically insuperable obstacle is rearrangement of ergotamine under the experimental conditions, forming a stereoisomer by inversion at the C-8 position. The equilibrium of ergotamine in equilibrium ergotaminine found in human plasma remains stable under the incubation conditions of the radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6735611     DOI: 10.1016/0047-0740(84)90040-8

Source DB:  PubMed          Journal:  Int J Nucl Med Biol        ISSN: 0047-0740


  5 in total

1.  Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.

Authors:  J N de Hoon; K A Poppe; H H Thijssen; H A Struijker-Boudier; L M Van Bortel
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

2.  Pharmacokinetics of intranasally-administered dihydroergotamine in the rat.

Authors:  D T Lau; Z Yu; R L Aun; A E Hassell; F L Tse
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.

Authors:  W H Aellig; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.

Authors:  P A Wyss; J Rosenthaler; E Nüesch; W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.